This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
TyRx Pharma (drug-eluting devices) has raised $25mm through the closing of its Series E venture round. Clarus Ventures and Pappas Ventures co-led the financing and will each gain representation on the company's board. TyRx will use the money to launch its recently FDA-cleared AIGISrx, an implantable device that holds a pacemaker or implantable cardioverter defibrillator in place and contains the antibacterial compounds rifampin and minocycline to lower the risk of infections.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?